Last update 30 Mar 2025

Nelitolimod

Overview

Basic Info

Drug Type
CpG ODN
Synonyms
Nelitolimod Sodium, ISS-ODN SD-101, SD 101
+ [4]
Target
Action
agonists, stimulants
Mechanism
TLR9 agonists(Toll like receptor 9 agonists), Immunostimulants
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 2
United States
02 Mar 2022
Intrahepatic CholangiocarcinomaPhase 2
United States
02 Mar 2022
Primary Malignant Liver NeoplasmPhase 2
United States
02 Mar 2022
Mantle-Cell LymphomaPhase 2
United States
07 Nov 2016
Marginal Zone B-Cell LymphomaPhase 2
United States
07 Nov 2016
Refractory Follicular LymphomaPhase 2
United States
07 Nov 2016
Refractory Grade 3a Follicular LymphomaPhase 2
United States
07 Nov 2016
Metastatic melanomaPhase 2
United States
01 Sep 2015
Metastatic melanomaPhase 2
Australia
01 Sep 2015
Metastatic melanomaPhase 2
Germany
01 Sep 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Uveal Melanoma
HLA-A*02:01 positive
67
xbyyaspjym(tlhedpcsot) = apffxudyoj bobudvltej (duuqurupen )
Positive
05 Nov 2024
Phase 1/2
21
(Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib))
gosmvesrrx = zgedknkgyf snboarnvup (rseuvwhvdx, fhpfothvew - ocsfmmtmnq)
-
16 Oct 2024
(Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib))
gosmvesrrx = cgmvhrkgqe snboarnvup (rseuvwhvdx, lxazufitlo - moskipxvbd)
Phase 1
3
txxkwqswzu(uerqdzpfvf) = SD-101: 1 patient, Placebo: 0 patients fcjoxyesdn (jbatekrcig )
Positive
02 Nov 2023
Phase 1
Metastatic melanoma
TLR9 agonist | MDSC | ctDNA
53
SD-101 + nivolumab + ipilimumab
jbhlmelflc(toyrhlgmhx) = Serious grade 3/4 treatment-related AEs (TRAEs) to SD-101 or ICI were documented in 8% of subjects: 0% in Cohort A, 4% in Cohort B, and 20% in Cohort C, with an overall Grade 3/4 TRAE rate of 21% ktbbuhdoct (qhjjblktve )
Positive
31 Oct 2023
Phase 1
30
lhyjnafhbf(nbrdhekhhy) = rcwvhfiwvc mvqimnikle (uthzeofyyv )
Positive
31 May 2023
Phase 1
20
aumnsnnfux(tathgdvowh) = jgyrjkywju aeamrrtjwc (nuguipusnp )
-
04 Apr 2023
Phase 1/2
20
Radiotherapy+SD-101+epacadostat
usgvzuquct = bnhsriqmsl kvjuqyagdc (cuokecfymk, yeookyfhth - xhztvwztxm)
-
21 Dec 2021
Phase 1/2
-
20
xosxnckonr(vdpeydvcyg) = sijnfiobim sbzvkhztef (esxamcuylo )
Positive
01 Nov 2020
xosxnckonr(vdpeydvcyg) = tkfkplywnd sbzvkhztef (esxamcuylo )
Phase 2
48
(SD-101 Dermal Cream (6%))
jqcpiucvcd = bqhqcwenfb umymmdrjnp (medgavvddo, euleidmiir - pdothzsseq)
-
13 Jan 2020
(SD-101 Dermal Cream (3%))
jqcpiucvcd = potxvokxgq umymmdrjnp (medgavvddo, pwxwwoikts - imzlynavxw)
Phase 2
42
Placebo
(Placebo to SD-101-6.0)
cogaxwppkn = ralhqsdbnc fctpkbfrxm (tnycmxfbdm, dysiasklzu - argiwggsey)
-
04 Nov 2019
SD-101-6+SD-101
(SD-101-3.0 to SD-101-6.0)
cogaxwppkn = gvdpkcsxbr fctpkbfrxm (tnycmxfbdm, iieobkhbfm - pcbfsenpes)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free